I saw your previous posts where you said that .20 would be a fair value in a buyout. I disagree.
That the Chemsat system is already approved in Europe and is generating small but increasing amount of revenue is sufficient for a valuation higher than $100M. It's only a matter of time before other countries adopt this life-extending treatment -- and with Single Payer insurance over there, once one or two dominos fall down the rest should follow rather easily (unlike here in the USA where drug companies have to negotiate deals with tens or hundreds of different insurers each with different terms).
Your .20 valuation also doesn't take into account the massive potential if/when it's approved in the United States.
News 
Market Data 
Discover 
